Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sanofi (SNY) Gross Margin (2016 - 2026)

Sanofi's Gross Margin history spans 16 years, with the latest figure at 77.13% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 85.0% to 77.13% in Q1 2026 year-over-year; TTM through Mar 2026 was 76.98%, a 96.0% decrease, with the full-year FY2025 number at 77.17%, up 151.0% from a year prior.
  • Gross Margin hit 77.13% in Q1 2026 for Sanofi, down from 81.66% in the prior quarter.
  • Over the last five years, Gross Margin for SNY hit a ceiling of 83.31% in Q4 2024 and a floor of 72.0% in Q4 2022.
  • Historically, Gross Margin has averaged 76.35% across 5 years, with a median of 76.02% in 2024.
  • Biggest five-year swings in Gross Margin: skyrocketed 853bps in 2024 and later plummeted -165bps in 2025.
  • Tracing SNY's Gross Margin over 5 years: stood at 72.0% in 2022, then grew by 4bps to 74.78% in 2023, then rose by 11bps to 83.31% in 2024, then decreased by -2bps to 81.66% in 2025, then dropped by -6bps to 77.13% in 2026.
  • Business Quant data shows Gross Margin for SNY at 77.13% in Q1 2026, 81.66% in Q4 2025, and 78.02% in Q3 2025.